Doxazosin increases low density lipoprotein receptor activity.
The effect of the alpha 1 adrenoreceptor antagonist doxazosin on low density lipoprotein (LDL) receptor activity, has been studied in cultured skin fibroblasts. Doxazosin at a concentration of 10(-5) M significantly increased the LDL receptor activity. The possible clinical implications of this observation are discussed.
Leren
T P
TP
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D002460:Cell Line; D002478:Cells, Cultured; D002675:Child, Preschool; D017292:Doxazosin; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism*; D011224:Prazosin / Q000031:analogs & derivatives / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000187:drug effects* / Q000378:metabolism; D018110:Receptors, Lipoprotein
D000317:Adrenergic alpha-Antagonists; D008077:Lipoproteins, LDL; D011799:Quinazolines; D011956:Receptors, Cell Surface; D018110:Receptors, Lipoprotein; D017292:Doxazosin; D011224:Prazosin